Literature DB >> 17698856

Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese.

Kuo-Liong Chien1, Hsiu-Ching Hsu, Ta-Chen Su, Ming-Fong Chen, Yuan-Teh Lee, Frank B Hu.   

Abstract

The aim of our study was to compare apolipoprotein B (apoB), non-high density lipoprotein cholesterol (nonHDL-C), low density lipoprotein cholesterol (LDL-C), and other lipid markers as predictors of coronary heart disease (CHD) in Chinese. Overall, 122 individuals developed CHD during a median 13.6 years of follow-up in 3,568 adult participants from a community-based cohort. The multivariate relative risk of CHD in the highest quintile compared with the lowest quintile was 2.74 [95% confidence interval (CI), 1.45-5.19] for apoB, 1.98 (95% CI, 1.00-3.92) for nonHDL-C, and 1.86 (95% CI, 1.00-3.49) for LDL-C (all tests for trend, P < 0.05). ApoB also had the highest receiver operator characteristic curve area (0.63; 95% CI, 0.58-0.68) in predicting CHD. When apoB and nonHDL-C were mutually adjusted, only apoB was predictive; the relative risk was 2.80 (95% CI, 1.31-5.96; P = 0.001) compared with 1.09 (95% CI, 0.49-2.40; P = 0.75) for nonHDL-C. Compared with the lowest risk, participants with the highest apoB and total cholesterol/HDL-C had a 3-fold increased risk of developing CHD (relative risk = 3.21; 95% CI, 1.45-7.14). These data provide strong evidence that apoB concentration was a better predictor of CHD than other lipid markers in Chinese.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698856     DOI: 10.1194/jlr.M700213-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  28 in total

1.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

2.  Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Authors:  Charles R Harper; Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 3.  Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.

Authors:  Christopher C Imes; Melissa A Austin
Journal:  Biol Res Nurs       Date:  2012-04-23       Impact factor: 2.522

4.  The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China.

Authors:  Wanhua Xu; Rong Li; Suhua Zhang; Lilin Gong; Zhihong Wang; Wei Ren; Chenxi Xia; Qifu Li
Journal:  Endocrine       Date:  2012-01-15       Impact factor: 3.633

5.  Acyclic Isoprenoid Attenuates Lipid Anomalies and Inflammatory Changes in Hypercholesterolemic Rats.

Authors:  Ramalingam Sundaram; Purusothaman Ayyakkannu; Karuppiah Muthu; Sohara Parveen Nazar; Shanthi Palanivelu; Sachdanandam Panchanatham
Journal:  Indian J Clin Biochem       Date:  2018-06-13

6.  Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients.

Authors:  P Liting; L Guoping; C Zhenyue
Journal:  Herz       Date:  2014-11-07       Impact factor: 1.443

Review 7.  Mini-Review of the Chin-Shan Community Cardiovascular Cohort Study in Population Health Research in Taiwan.

Authors:  Kuo-Liong Chien
Journal:  Acta Cardiol Sin       Date:  2017-05       Impact factor: 2.672

8.  Goal attainments and their discrepancies for low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B) in over 2,000 Chinese patients with known coronary artery disease or type 2 diabetes.

Authors:  Yong-Ming He; Xiang-Jun Yang; Xin Zhao; Hai-Feng Xu
Journal:  Cardiovasc Diagn Ther       Date:  2015-04

Review 9.  Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients.

Authors:  Yi-Heng Li; Ting-Hsing Chao; Ping-Yen Liu; Kwo-Chang Ueng; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

10.  A prediction model for type 2 diabetes risk among Chinese people.

Authors:  K Chien; T Cai; H Hsu; T Su; W Chang; M Chen; Y Lee; F B Hu
Journal:  Diabetologia       Date:  2008-12-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.